| 24/03/25 | 07:00:10 | 24 Mar 2025 | | First Patient Safety |
| 17/03/25 | 07:00:09 | 17 Mar 2025 | | Recruitment of Second Patient for Clinical Trials |
| 13/03/25 | 15:10:42 | 13 Mar 2025 | | Conversion of convertible loan notes |
| 11/03/25 | 07:00:08 | 11 Mar 2025 | | Institutional investment |
| 24/02/25 | 07:00:08 | 24 Feb 2025 | | First-in-Human Treatment with HG-CT-1 |
| 19/02/25 | 16:50:45 | 19 Feb 2025 | | Issue of convertible loan notes |
| 31/01/25 | 09:35:52 | 31 Jan 2025 | | Total Voting Rights |
| 08/01/25 | 07:00:05 | 8 Jan 2025 | | Placing to raise £340,000 |
| 02/01/25 | 07:00:07 | 2 Jan 2025 | | Change of Company Secretary and Registered Office |
| 31/12/24 | 07:00:05 | 31 Dec 2024 | | Total Voting Rights |
| 30/12/24 | 07:00:02 | 30 Dec 2024 | | Opening of First Clinical Site |
| 19/12/24 | 07:00:06 | 19 Dec 2024 | | Ultrafast CAR-T Manufacturing |
| 10/12/24 | 16:10:59 | 10 Dec 2024 | | Admission of New Ordinary Shares and New ISIN |
| 09/12/24 | 13:30:29 | 9 Dec 2024 | | Result of Extraordinary General Meeting |
| 09/12/24 | 07:00:05 | 9 Dec 2024 | | Site Initiation Visit Completed |
| 06/12/24 | 07:00:01 | 6 Dec 2024 | | CBR Macrophage Delivery Update |
| 29/11/24 | 07:00:02 | 29 Nov 2024 | | Total Voting Rights |
| 22/11/24 | 12:49:00 | 22 Nov 2024 | | Notice of Extraordinary General Meeting |
| 22/11/24 | 07:00:05 | 22 Nov 2024 | | IRB Approval for Phase I Clinical Trial |
| 11/11/24 | 07:00:08 | 11 Nov 2024 | | Institutional Investment |
| 30/10/24 | 07:00:02 | 30 Oct 2024 | | Schedule for Phase I Clinical Trial Opening |
| 02/10/24 | 11:19:04 | 2 Oct 2024 | | Strategic Investment from Prevail Partners, LLC |
| 27/09/24 | 07:00:07 | 27 Sept 2024 | | Half-year Report |
| 09/09/24 | 07:00:05 | 9 Sept 2024 | | FLT3 Assay Ready for Phase I Trials at MD Anderson |
| 02/09/24 | 07:00:09 | 2 Sept 2024 | | CDX Development Update |
| 28/08/24 | 07:00:02 | 28 Aug 2024 | | Presentation at CBD S&T Conference |
| 29/07/24 | 07:00:10 | 29 Jul 2024 | | Macrophage-Directed Therapies Summit Presentation |
| 27/06/24 | 16:39:38 | 27 Jun 2024 | | Result of Annual General Meeting |
| 17/06/24 | 07:00:10 | 17 Jun 2024 | | Operations Update |
| 03/06/24 | 07:00:12 | 3 Jun 2024 | | Posting of Annual Report & Notice of AGM |
| 25/04/24 | 07:00:11 | 25 Apr 2024 | | Final Results |
| 28/03/24 | 07:00:04 | 28 Mar 2024 | | Total Voting Rights |
| 29/02/24 | 07:00:05 | 29 Feb 2024 | | Placing to Raise US$4.2 million |
| 16/02/24 | 07:00:04 | 16 Feb 2024 | | CBR Brain Delivery |
| 14/02/24 | 07:00:04 | 14 Feb 2024 | | CBR Intranasal Delivery |
| 09/02/24 | 07:00:03 | 9 Feb 2024 | | FDA Consents to Phase I Trials of HEMO-CAR-T |
| 02/02/24 | 07:00:02 | 2 Feb 2024 | | Approval and Issuance of U.S. Conditioning Patent |
| 16/01/24 | 07:00:01 | 16 Jan 2024 | | Submission of Complete Response to Clinical Hold |
| 08/01/24 | 07:00:03 | 8 Jan 2024 | | HEMO-CAR-T Process Qualification Run Completed |
| 28/11/23 | 12:19:37 | 28 Nov 2023 | | Placing to Raise £534,375 |
| 27/11/23 | 07:00:08 | 27 Nov 2023 | | CBR Expanded to Treatment of Cancer |
| 15/11/23 | 07:00:06 | 15 Nov 2023 | | Lentivirus Re-manufacturing Completed |
| 31/10/23 | 07:00:06 | 31 Oct 2023 | | Total Voting Rights |
| 28/09/23 | 12:28:01 | 28 Sept 2023 | | Half-year Report |
| 18/09/23 | 07:00:04 | 18 Sept 2023 | | Strategic Investment from Prevail Partners, LLC |
| 14/09/23 | 07:00:03 | 14 Sept 2023 | | Clinical Hold Lift Plan is accepted by FDA |
| 08/09/23 | 17:11:57 | 8 Sept 2023 | | CBR Patent Application Update |
| 10/07/23 | 07:00:05 | 10 Jul 2023 | | Full FDA Review for HEMO-CAR-T IND |
| 30/06/23 | 16:07:40 | 30 Jun 2023 | | Result of Annual General Meeting |
| 02/06/23 | 14:01:47 | 2 Jun 2023 | | Posting of Annual Report & Notice of AGM |
